Released May 4, 2023, before the open
10-Q filed May 4, 2023, 34 days after period end · 0001171843-23-002868
Q1 2023 · 10-Q
Revenue—
Net Income-$7.84M-$7.84M N/M vs Q1 2022N/M vs Q4 2022
EPS, diluted—
Operating Income-$9,711,000N/M
Operating Cash Flow-$12,229,000N/M
Free Cash Flowderived-$12,229,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Net Income | -$7.84M | -$7.16M | -$7.42M | -$6.40M |
| EPS Diluted | — | -$0.07 | -$0.14 | -$0.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR